贝伐珠单抗联合多西他赛治疗HER-2阴性复发转移性乳腺癌的临床疗效

目的 观察贝伐珠单抗联合多西他赛治疗人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）阴性复发转移性乳腺癌的临床疗效。方法  79例HER-2阴性复发转移性乳腺癌患者根据不同化疗方案分为两组，观察组42例给予贝伐珠单抗联合多西他赛治疗，对照组37例给予多西他赛单药治疗，观察两组患者治疗后的临床疗效和1年、2年生存率及生存期。 结果 观察组总有效率为59.52%，对照组为37.84%，两组比较差异无统计学意义（P＞0.05）；观察组患者部分缓解率为47.62%，显著高于对照组的24.32%（P＜0.05）；观察组患者2年生存率为40.28%，高于对照组的16.22%（P＜0.05）；观察组患者贫血、血小板减少的发生率显著高于对照组（P＜0.05）。 结论 贝伐珠单抗联合多西他赛治疗HER-2阴性复发转移性乳腺癌的疗效较好，可提高患者生存率和生存期，但对患者血液系统影响较为明显，值得临床重视。

Efficacy of bevacizumab combined with docetaxel to treat Her-2-negative metastatic breast cancer

Objective To investigate the efficacy of bevacizumab in combination with docetaxel to treat Her-2-negative metastatic breast cancer. Methods  Patients received either bevacizumab in combination with docetaxel（n＝42） or docetaxel（n=37）. Curative outcomes were assessed after 4 cycles of therapy during follow-up lasting 3-24 months. Results The total efficacy rate was 59.52% in the group receiving bevacizumab and docetaxel and 37.84% in the group receiving docetaxel，which was a significant difference（P>0.05）. The positive response rate was significantly higher in the group receiving bevacizumab and docetaxel （26.19 vs 24.32%，P<0.05），as was the 2-year survival rate（40.28 vs 16.22%，P<0.05）. At the same time，incidence of anemia and thrombocytopenia was significantly higher in the group receiving bevacizumab and docetaxel. Conclusion Bevacizumab combined with docetaxel can show high efficacy against Her-2-negative metastatic breast cancer，as well as improve the survival rate and survival time. Future studies need to examine ways to reduce the adverse effects of the therapy on blood components.